

CV GIOVANNI MONTELEONE

Date /Place of birth:	27 November, 1964, Catanzaro (Italy)
Residence:	Grottaferrata, Via XXIV Maggio n. 128, Rome (Italy) 00046
Education:	Degree in Medicine in 1991 University of Reggio Calabria, Catanzaro (Italy)
Specialty:	Gastroenterology in 1996 University of Reggio Calabria, Catanzaro (Italy)
PhD:	Experimental Immunology in 2002 University Magna Graecia, Catanzaro (Italy)

PRESENT POSITION:

Since 2014: Full Professor in Gastroenterology, University of Rome Tor Vergata, Rome (Italy)

Address: Systems Medicine Department, University of Rome Tor Vergata, Via Montpellier n. 1, 00133 Rome (Italy)

Since November 2015: Chief of Gastroenterology Unit, “Fondazione PTV -Policlinico Tor Vergata”

Since November 2019: Director of School of Gastroenterology Specialization, University of Rome Tor Vergata, Rome (Italy)

Address:

Via Montpellier n.1, 00133 Rome (Italy)

Viale Oxford n. 81, 00133 Rome (Italy)

Phone +39.06.20903702

Fax: + 39.06.20904437

E-mail: gi.monteleone@med.uniroma2.it

EMPLOYMENTS:

- **1991-1998:** Research Fellow in Gastroenterology, University of Reggio Calabria, Catanzaro (Italy)
- **1998:** Visiting Fellow, Department of Paediatric Gastroenterology, Mucosal Immunology Laboratory, School of Medicine, Queen Mary Westfield College, London (UK)
- **1999-2000:** Research Assistant, Department of Paediatric Gastroenterology, Mucosal Immunology Laboratory, School of Medicine, Queen Mary Westfield College, London (UK)
- **2000-2001:** Research Assistant, Division of Infection, Allergy, Inflammation and Repair, School of Medicine, Southampton General Hospital, Southampton (UK)
- **2002-2003:** Research Assistant, Department of Internal Medicine, University of Rome Tor Vergata, Rome (Italy)
- **2003-2006:** Assistant Professor, Department of Internal Medicine, University of Rome Tor Vergata, Rome (Italy)
- **2007-2014:** Associate Professor in Gastroenterology, University of Rome Tor Vergata, Rome (Italy)
- **SINCE 2014 :** Ordinary Professor in Gastroenterology, University of Rome Tor Vergata, Rome (Italy)

EDITORIAL ACTIVITY:

- Editorial member of “ World Journal of Gastroenterology” (since 2004)
- Editorial member of “Journal of Crohn’s disease and colitis” (since 2007)

- Editorial member of “Clinical Science” (since 2008)
- Editorial member of “Digestive Liver and Disease” (2008-2010)
- Editorial member of “GUT” (since 2009)
- Editorial member of “Journal The World Journal of Gastrointestinal Pharmacology and Therapeutics” (since 2012)
- Editorial member of “Journal of Traslational Internal Medicine” (since 2014)
- Editorial member: Journal of Liver and Clinical Research (since 2014)

REVIEWER OF:

Gastroenterology, Gut, American Journal of Gastroenterology, The Journal of Clinical Investigation, The Journal of Immunology, Neoplasia, International Immunology, Scandinavian Journal of Gastroenterology, • Clinical Experimental Immunology, European Journal of Immunology, Digestive and Liver Disease, •Inflammatory Bowel Diseases, European Journal of Gastroenterology, Digestive Diseases and Science, Oncogene, Nature, Nature Medicine, J Exp Med, Journal of Pediatric Gastroenterology and Nutrition, World Journal of Gastroenterology, American Journal of Pathology, Disease Colon & Rectum, Apoptosis, Eur Journal of Cancer.

MEMBER OF:

- The Steering Committee of Italian Society of Gastroenterology (SIGE)
- The Mucosal Immunology Society
- The editorial board for the web site of Italian Society of Gastroenterology (SIGE)
- The Steering Committee of Italian group of Inflammatory Bowel Disease

TEACHING ACTIVITY:

- Teaching of students in: Medicine, Medical Biotechnology and Nurse courses, University of Rome Tor Vergata, Rome (Italy)
- Teaching of fellows in Gastroenterology, University of Rome Tor Vergata, Rome (Italy)
- Teaching of

CLINICAL ACTIVITY:

Clinical activity has been performed as Gastroenterologist at the Gastroenterology Unity of the University of Catanzaro and at the Gastroenterology Unity of the University Tor Vergata in Rome.

RESEARCH ACTIVITY:

Research activity has been performed at the University of Rome Tor Vergata in Rome in collaborations with the following groups:

1. Immunology Laboratory of the Istituto Superiore di Sanità, Rome, Italy, directed by Dr. Monica Boirivant
2. Laboratory of Immunology, Faculty of Medicine and Surgery, University of Rome Tor Vergata Rome, Italy, directed by Prof. Roberto Testi
3. Gastroenterology Laboratory of the Department “Internistica Clinica e Sperimentale-Gastroenterologia”, II University of Naples, Italy, Prof. Marco Romano
4. Pathological Anatomy Unit, Faculty of Medicine and Surgery, University of Rome Tor Vergata Rome, Italy, Prof. Piero Palmieri
5. Laboratory of Immunology, I. Medical Clinic, University of Mainz, Germany, directed by Prof. Markus Neurath
6. Laboratory of Division of Infection, Inflammation and Repair, University of Southampton, Southampton, UK, directed by Dr. Sylvia Pender

7. Laboratory of Department Internal Medicine, Faculty of Medicine and Surgery, University of Rome Tor Vergata Rome, Rome, Italy, directed by Prof. Giorgio Federici
8. Pediatrics, Faculty of Medicine and Surgery, University “La Sapienza”, Rome, Italy, Prof. Salvatore Cucchiara
9. Laboratory of the Department of Experimental Medicine, Faculty of Medicine and Surgery, University “Magna Graecia”, Catanzaro, Italy, Prof. Francesco Luzzza
10. Dermatology Laboratory of the Department of Interna Medicine, University of Rome Tor Vergata Rome, Italy, Prof. Sergio Chimenti and Prof. A. Costanzo
11. Center for the study and treatment of celiac disease, Foundation “IRCCS Policlinico San Matteo”, University of Pavia, Italy, Prof. G Corazza and Prof. A. Di Sabatino
12. Gastroenterology Unit, Foundantion “IRCCS Ca' Granda”, “Ospedale Maggiore Policlinico”, Milan, Italy, Dr. F. Caprioli
13. Laboratory of Immunology, University “Rene Descartes Paris 5, INSERM U580, Hopital Necker-Enfants Malades, Paris, directed by Dr. Lucienne Chatenoud
14. Mucosal Immunity Section, Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA, diretto dal Dr. Warren Strober
15. Institute of Cell and Molecular Science, Barts and the London School of Medicine and Dentistry, London, UK., diretto dal Prof. Thomas T MacDonald

AWARDS

- YOUNG SCIENTIST AWARD, 3rd UEGW, Oslo, Norway, 1994
- Tilde Fiorentini” AWARD 2000
- Aldo Torsoli AWARD 2005
- Scanno for Medicine AWARD , XLIII edition, 2016
- Gold Medal for Merit of Public Health, Roma, 2016

PRINCIPAL INVESTIGATOR OF THE FOLLOWING RESEARCH PROJECTS :

- Broad Medical Research Program: 2004-2005- Role of Smad7, an inhibitor of TGF-beta1 signalling, in chronic intestinal Inflammation
- “Ministero dell’Istruzione, dell’Università e della Ricerca”, Italy, 2004-2006, -Expression and regulation of foxp3-regulatory cells in inflammatory bowel disease-
- “Associazione Italiana per la Ricerca sul Cancro”: 2004–2007 Chemoprophylactic effect of mesalazine in colorectal cancer -.
- Broad Medical Research Program: 2005-2007- Interleukin-21 triggers inflammatory pathways in the gut: relevance for human inflammatory bowel diseases-
- Istituto Superiore di Sanità, 2006. Strategie di uso di batteri probiotici, prodotti batterici e parassitari per la terapia delle malattie autoimmuni ed allergiche.
- SEVENTH FRAMEWORK PROGRAMME, EUROPEAN UNION, No. 200931: Mucosal proteases and their inhibitors in inflammatory bowel disease: From etiopathogenetic insight to innovative therapy. 2008-2011.
- SEVENTH FRAMEWORK PROGRAMME, EUROPEAN UNION, No. 202020, IPODD. IBD: Protease offer new targets for drug discovery.
- Broad Medical Research Program: 2008-2010- Antagonistic effects of Interleukin-25 on CD14+ cell cytokine responses in the gut.
- “Associazione Italiana per la Ricerca sul Cancro”: 2009–2012. Regulation of colon carcinogenesis by 2-methoxy-5-amino benzoylhydroxamic acid, a derivative of mesalazine.
- Broad Medical Research Program: 2010-2012-Effect of Smad7 antisense oligonucleotide on clinical, laboratory and immunological variables in patients with active Crohn’s disease: the first human experience.

- “Associazione Italiana per la Ricerca sul Cancro”: 2013–2016 Smad7 as a molecular target for pharmacological intervention in colorectal cancer.
- “Associazione Italiana Celiachia”: 2016–2019 Role of mTor kinase cascade in celiac disease.
- “Associazione Italiana per la Ricerca sul Cancro”: 2017–2020 Interleukin-34 sustain pro-tumorigenic signal in colon cancer tissue.

INVENTOR OF THE FOLLOWING PATENTS

- MEDICAL FIELD PCT Pub. No. WO2004/087920; Grant_Date 19/12/2007; Inventors Giovanni Monteleone.
- Epitopi antigenici dell'Interleuchina-21, anticorpi relativi e loro uso in campo medico. Filing_date 29/11/2004 Patent_number 1351588; Grant_Date 13/01/2009; Inventors Monteleone Giovanni.
- A treatment for inflammatory disease. Filing_date 04/04/2008; Patent_number EP2106801; Inventors Monteleone Giovanni.
- Binding proteins and methods of making and using same; Filing_date 28/04/2008; Application_no EP08425294.9; Inventors Monteleone Giovanni.
- Treatments for inflammatory disease; Filing_date 06/06/2008; Application_no EP08157799.1; Inventors Monteleone Giovanni.
- Methods for preventing or reducing carcinogenesis; Filing_date 01/07/2009; PCT App. No. PCT/EP2009/008633. Inventors Bellinvia Salvatore, Baroni Sergio, Monteleone Giovanni, Viti Francesca
- METHODS FOR PREDICTING RESPONSIVENESS TO ANTI-SMAD7 THERAPY
Europe Provisional App. No. EP11425233.1; Filing Date 15th September 2011(Pending)
Europe Provisional App. No. EP11425234.9; Filing Date 15th September 2011 (Pending)
United States Provisional App. No. 61/576,556; Filing Date 16th December 2011 (Pending)
United States Provisional App. No. 61/576,547; Filing Date 16th December 2011(Pending).
Inventors: Monteleone Giovanni, Bellinvia Salvatore, Viti Francesca.
- METHODS OF TREATING DIABETES AND/OR PROMOTING SURVIVAL OF PANCREATIC ISLETS AFTER TRANSPLANTATION
United States Provisional App. No. US61625904; Filing Date 18th April 2012
Inventors: Monteleone Giovanni, Buchwald Peter, Inverardi Luca, Pileggi Antonello, Ricordi Camillo, Tomei Alice.

DEVELOPMENT OF DRUG PRODUCTS:

Scientific research has contributed to the development of a pharmacological product, containing an antisense oligonucleotide against Smad7 for the treatment of patients with active Crohn's disease.

Rome, November 2021

GIOVANNI MONTELEONE, MD, Phd

